These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33811367)

  • 1. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
    Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
    Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
    Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
    Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
    Chatterjee S; Majumder A; Ray S
    Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
    Ezhilarasan D
    Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    Vuppalanchi R; Caldwell SH; Pyrsopoulos N; deLemos AS; Rossi S; Levy C; Goldberg DS; Mena EA; Sheikh A; Ravinuthala R; Shaikh F; Bainbridge JD; Parmar DV; Chalasani NP
    J Hepatol; 2022 Jan; 76(1):75-85. PubMed ID: 34487750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.
    Vuppalanchi R; González-Huezo MS; Payan-Olivas R; Muñoz-Espinosa LE; Shaikh F; Pio Cruz-Lopez JL; Parmar D
    Clin Transl Gastroenterol; 2021 Mar; 12(4):e00327. PubMed ID: 33769355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.